替考拉宁临床应用合理性分析

发布时间：2018-01-02 10:40

本文关键词：替考拉宁临床应用合理性分析　出处：《临床药物治疗杂志》2016年03期 　论文类型：期刊论文

【摘要】：目的:调查和分析临床应用替考拉宁的用药合理性,为替考拉宁的临床合理应用提供参考依据。方法:通过电子病历系统筛选2015年1月至12月期间使用替考拉宁的住院患者,提取患者临床资料并进行统计分析。结果:108例患者应用替考拉宁治疗,以肺部感染为主,占68.52%。病原学标本送检率达98.1%,送检样本阳性率为45.4%,根据细菌培养和药敏试验结果选用替考拉宁的37例(34.3%)。47例(43.5%)患者替考拉宁用药存在不合理之处,主要表现为未予起始负荷量(89.4%)、负荷剂量给药方案不合理(17.0%)以及未根据肾功能水平调整剂量(19.1%)等。结论:应继续规范替考拉宁的临床使用及给药方案,特别是负荷剂量及肾功能不全患者的剂量调整,提升替考拉宁合理使用水平。
[Abstract]:Objective: To investigate and analyze the clinical application of teicoplanin in rational drug use, to provide reference for clinical rational application of teicoplanin. Methods: the electronic medical records system from January 2015 to December during the screening of teicoplanin in hospitalized patients, clinical data analysis and statistical extraction patients. Results: patients treated with teicoplanin in the treatment of 108 cases with pulmonary infection, accounted for the etiology of 68.52%. specimen rate was 98.1%, the positive rate of inspection samples was 45.4%, according to the results of bacterial culture and drug sensitive test with teicoplanin in 37 cases (34.3%).47 cases (43.5%) patients with teicoplanin medication unreasonable, mainly for not starting load (89.4%), the loading dose regimen (unreasonable 17%) according to the level of renal function and no dose adjustment (19.1%). Conclusion: we should continue to regulate the clinical use of teicoplanin and dosing regimen, especially load Dose and renal dysfunction in patients with dose adjustment, improve the level of rational use of teicoplanin.

【作者单位】：北京医院药学部药物临床风险与个体化应用评价北京市重点实验室国家呼吸系统疾病临床医学研究中心;
【基金】：临床药学科国家临床重点专科建设项目(2014-2018年)
【分类号】：R978
【正文快照】： 替考拉宁(teicoplanin)是一种新型糖肽类抗菌药物,对革兰阳性细菌具有强大的抗菌活性,临床主要用于对青霉素或头孢菌素耐药的革兰阳性细菌所致的严重感染。因其抗菌作用强、肾毒性低的优势,临床应用日益增多,特别是常用于肾功能不全的老年严重感染患者的治疗[1]。本调查对北京

【相似文献】